BlackRock Group’s Travere Therapeutics TVTX Stock Holding History

BlackRock Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$314K	Buy	16,603 +1,155	+7%	+$23.6K	﹤0.01%	2517
2016 Q3	$346K	Buy	15,448 +1,219	+9%	+$23.2K	﹤0.01%	2442
2016 Q2	$254K	Sell	14,229 -165	-1%	-$2.67K	﹤0.01%	2487
2016 Q1	$197K	Buy	14,394 +5,093	+55%	+$77.3K	﹤0.01%	2586
2015 Q4	$179K	Buy	9,301 +2,541	+38%	+$50.8K	﹤0.01%	2546
2015 Q3	$137K	Sell	6,760 -1,596	-19%	-$47.3K	﹤0.01%	2625
2015 Q2	$277K	Buy	+8,356	New	+$229K	﹤0.01%	2477
2014 Q2	–	Sell	-15,502	Closed	-$329K	–	2866
2014 Q1	$329K	Buy	+15,502	New	+$238K	﹤0.01%	2347

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Group's TVTX Position: Q4 2016 in Review

BlackRock Group increased its Travere Therapeutics (TVTX) stake by 7.5% in Q4 2016, buying an estimated $23.6K and bringing the position to 16,603 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #2517.

BlackRock Group first reported a position in TVTX in Q1 2014 and has held it in 8 quarters since. The position peaked at $346K in Q3 2016. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

BlackRock Group held 16,603 shares of Travere Therapeutics worth $314K as of Q4 2016.
BlackRock Group bought 1,155 Travere Therapeutics shares in Q4 2016, an estimated $23.6K.
Travere Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2517 holding.
BlackRock Group first reported a position in Travere Therapeutics in Q1 2014 and has held it in 8 quarters since.
BlackRock Group's Travere Therapeutics position peaked at $346K in Q3 2016.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.